share_log

Rock Star Growth Puts BeiGene (NASDAQ:BGNE) In A Position To Use Debt

Rock Star Growth Puts BeiGene (NASDAQ:BGNE) In A Position To Use Debt

搖滾巨星成長使百濟神州(納斯達克股票代碼:BGNE)有能力使用債務
Simply Wall St ·  01/18 07:43

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it seems the smart money knows that debt - which is usually involved in bankruptcies - is a very important factor, when you assess how risky a company is. Importantly, BeiGene, Ltd. (NASDAQ:BGNE) does carry debt. But should shareholders be worried about its use of debt?

傳奇基金經理李露(由查理·芒格支持)曾經說過:“最大的投資風險不是價格的波動,而是你是否會遭受永久的資本損失。”因此,當你評估公司的風險時,看來聰明的貨幣知道債務(通常涉及破產)是一個非常重要的因素。重要的是,百濟神州有限公司(納斯達克股票代碼:BGNE)確實有債務。但是,股東是否應該擔心其債務的使用?

When Is Debt A Problem?

債務何時會成爲問題?

Debt is a tool to help businesses grow, but if a business is incapable of paying off its lenders, then it exists at their mercy. In the worst case scenario, a company can go bankrupt if it cannot pay its creditors. However, a more usual (but still expensive) situation is where a company must dilute shareholders at a cheap share price simply to get debt under control. Of course, debt can be an important tool in businesses, particularly capital heavy businesses. The first step when considering a company's debt levels is to consider its cash and debt together.

債務是幫助企業發展的工具,但如果企業無法還清貸款人,那麼債務就任由他們擺佈。在最壞的情況下,如果一家公司無法向債權人付款,它可能會破產。但是,更常見(但仍然昂貴)的情況是,公司必須以低廉的股價稀釋股東才能控制債務。當然,債務可以成爲企業,尤其是資本密集型企業的重要工具。考慮公司的債務水平的第一步是將其現金和債務放在一起考慮。

View our latest analysis for BeiGene

查看我們對百濟神州的最新分析

What Is BeiGene's Net Debt?

百濟神州的淨負債是多少?

The image below, which you can click on for greater detail, shows that BeiGene had debt of US$531.1m at the end of September 2023, a reduction from US$649.3m over a year. But on the other hand it also has US$3.17b in cash, leading to a US$2.64b net cash position.

您可以點擊下圖查看更多詳情,該圖片顯示,截至2023年9月底,百濟神州的債務爲5.311億美元,較去年同期的6.493億美元有所減少。但另一方面,它也有31.7億美元的現金,淨現金狀況爲26.4億美元。

debt-equity-history-analysis
NasdaqGS:BGNE Debt to Equity History January 18th 2024
NASDAQGS: BGNE 債券與股本比率歷史記錄 2024 年 1 月 18 日

How Strong Is BeiGene's Balance Sheet?

百濟神州的資產負債表有多強?

Zooming in on the latest balance sheet data, we can see that BeiGene had liabilities of US$1.28b due within 12 months and liabilities of US$478.3m due beyond that. On the other hand, it had cash of US$3.17b and US$354.6m worth of receivables due within a year. So it actually has US$1.77b more liquid assets than total liabilities.

放大最新的資產負債表數據,我們可以看到,百濟神州在12個月內到期的負債爲12.8億美元,之後到期的負債爲4.783億美元。另一方面,它有31.7億美元的現金和價值3.546億美元的應收賬款將在一年內到期。所以它實際上有17.7億美元 更多 流動資產超過總負債。

This short term liquidity is a sign that BeiGene could probably pay off its debt with ease, as its balance sheet is far from stretched. Simply put, the fact that BeiGene has more cash than debt is arguably a good indication that it can manage its debt safely. The balance sheet is clearly the area to focus on when you are analysing debt. But ultimately the future profitability of the business will decide if BeiGene can strengthen its balance sheet over time. So if you're focused on the future you can check out this free report showing analyst profit forecasts.

這種短期流動性表明,由於其資產負債表遠未捉襟見肘,百濟神州很可能會輕鬆還清債務。簡而言之,百濟神州的現金多於債務這一事實可以說是一個很好的跡象,表明它可以安全地管理債務。資產負債表顯然是分析債務時需要關注的領域。但最終,該業務的未來盈利能力將決定百濟神州能否隨着時間的推移加強其資產負債表。因此,如果您專注於未來,可以查看這份顯示分析師利潤預測的免費報告。

Over 12 months, BeiGene reported revenue of US$2.2b, which is a gain of 76%, although it did not report any earnings before interest and tax. Shareholders probably have their fingers crossed that it can grow its way to profits.

在過去的12個月中,百濟神州公佈的收入爲22億美元,增長了76%,儘管它沒有報告任何利息和稅前收益。股東們可能對它能夠實現盈利抱有疑慮。

So How Risky Is BeiGene?

那麼百濟神州有多危險?

By their very nature companies that are losing money are more risky than those with a long history of profitability. And we do note that BeiGene had an earnings before interest and tax (EBIT) loss, over the last year. Indeed, in that time it burnt through US$1.9b of cash and made a loss of US$959m. But at least it has US$2.64b on the balance sheet to spend on growth, near-term. BeiGene's revenue growth shone bright over the last year, so it may well be in a position to turn a profit in due course. Pre-profit companies are often risky, but they can also offer great rewards. When I consider a company to be a bit risky, I think it is responsible to check out whether insiders have been reporting any share sales. Luckily, you can click here ito see our graphic depicting BeiGene insider transactions.

就其本質而言,虧損的公司比盈利歷史悠久的公司風險更大。而且我們確實注意到,百濟神州去年出現了息稅前收益(EBIT)虧損。事實上,在那段時間裏,它消耗了19億美元的現金,損失了9.59億美元。但至少在短期內,它的資產負債表上有26.4億美元可用於增長。百濟神州的收入增長在去年大放異彩,因此它很可能有能力在適當的時候實現盈利。盈利前公司通常是有風險的,但它們也可以提供豐厚的回報。當我認爲一家公司有點風險時,我認爲它有責任檢查內部人士是否報告了任何股票銷售情況。幸運的是,你可以點擊這裏查看我們描繪百濟神州內幕交易的圖片。

When all is said and done, sometimes its easier to focus on companies that don't even need debt. Readers can access a list of growth stocks with zero net debt 100% free, right now.

當一切都說完之後,有時更容易將注意力集中在甚至不需要債務的公司上。讀者現在可以100%免費訪問淨負債爲零的成長型股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論